- Home
- LTRN vs ESLA Comparison
LTRN vs ESLA Comparison
Compare LTRN & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRN
- ESLA
- Stock Information
- Founded
- LTRN 2013
- ESLA 2021
- Country
- LTRN United States
- ESLA United States
- Employees
- LTRN N/A
- ESLA N/A
- Industry
- LTRN Biotechnology: Pharmaceutical Preparations
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LTRN Health Care
- ESLA Health Care
- Exchange
- LTRN Nasdaq
- ESLA Nasdaq
- Market Cap
- LTRN 36.0M
- ESLA 35.5M
- IPO Year
- LTRN 2020
- ESLA N/A
- Fundamental
- Price
- LTRN $3.89
- ESLA $0.87
- Analyst Decision
- LTRN Strong Buy
- ESLA Strong Buy
- Analyst Count
- LTRN 1
- ESLA 1
- Target Price
- LTRN $25.00
- ESLA $16.00
- AVG Volume (30 Days)
- LTRN 542.7K
- ESLA 17.4K
- Earning Date
- LTRN 08-07-2025
- ESLA 08-20-2025
- Dividend Yield
- LTRN N/A
- ESLA N/A
- EPS Growth
- LTRN N/A
- ESLA N/A
- EPS
- LTRN N/A
- ESLA N/A
- Revenue
- LTRN N/A
- ESLA N/A
- Revenue This Year
- LTRN N/A
- ESLA $101.09
- Revenue Next Year
- LTRN N/A
- ESLA N/A
- P/E Ratio
- LTRN N/A
- ESLA N/A
- Revenue Growth
- LTRN N/A
- ESLA N/A
- 52 Week Low
- LTRN $2.55
- ESLA $0.63
- 52 Week High
- LTRN $6.12
- ESLA $2.55
- Technical
- Relative Strength Index (RSI)
- LTRN 53.98
- ESLA 54.22
- Support Level
- LTRN $3.73
- ESLA $0.83
- Resistance Level
- LTRN $4.43
- ESLA $0.88
- Average True Range (ATR)
- LTRN 0.45
- ESLA 0.07
- MACD
- LTRN -0.01
- ESLA 0.01
- Stochastic Oscillator
- LTRN 55.64
- ESLA 88.89
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.